Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 50,05 € (+16,88%). La mediana è 50,50 € (+17,94%).

Acquista
  5
Mantieni
  1
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • HeartFlow: plaque analysis becomes main growth driver

    HeartFlow presented plaque analysis as its most important near-term growth driver at the Wells Fargo conference and projects about $30 million in revenue for 2026 versus $1.5 million in 2025. In Q2 2026 revenue rose 48% to over $64 million with a gross margin of roughly 82%. The company has about $250 million in cash, aims for profitability by mid-2028, and sees an expanded addressable market from $5 billion to $11 billion through expansion into asymptomatic high-risk patients; a broader product rollout including PCI Navigator is planned for 2027. » Altro su de.investing.com


  • Heartflow climbs to new record high of $51.26

    Heartflow stock reached an all-time high of $51.26 after strong gains in recent months (about +110% in 6 months, +73% year-to-date). In Q2 2026 the company reported adjusted earnings of -$0.07 per share and revenue up 48% to $64.1 million, with both metrics beating estimates. In response, Stifel raised its price target to $45.00 and reiterated a "Buy" rating, while some valuations consider the stock overvalued relative to fair value. » Altro su de.investing.com


  • Heartflow hits record high of $48.70 after strong Q2 results

    Heartflow shares rose to a record high of $48.70, about 1% below the 52-week high; the stock is up 86% over the past six months. In Q2 2026 the company beat expectations with adjusted EPS of -$0.07 (estimate -$0.19) and revenue rising 48% to $64.1 million. Stifel raised its price target to $45.00 and affirmed its "Buy" rating, while InvestingPro notes the stock may be overvalued at current levels. » Altro su de.investing.com


  • HeartFlow beats Q2 expectations, raises full-year guidance and stock jumps after hours

    HeartFlow reported an adjusted loss per share of $0.07 for Q2 2026, beating consensus by $0.12. Revenue rose 48% to $64.1 million and gross margin climbed to 83.3%, driven by strong plaque business and AI-powered automation. The company raised its full-year guidance to $246–250 million in revenue and a non-GAAP gross margin of about 82%; the stock rose roughly 16–17% after hours. While HeartFlow remains unprofitable, it expects to be cash-flow positive by mid-2028 and is showing accelerated revenue and margin growth. » Altro su de.investing.com


  • HeartFlow beats Q1 forecasts, raises full-year outlook — shares slightly weaker

    HeartFlow reported Q1 2026 EPS of -$0.16, beating the expected -$0.22; revenue rose 41% to $52.6 million. Non-GAAP gross margin improved to 80.5% and the non-GAAP net loss narrowed to $13.3 million. The company received positive feedback on new products such as the PCI Navigator and raised its 2026 revenue guidance to $228–232 million. Despite the results, the stock slipped 0.61% in after-hours trading. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, HeartFlow ha registrato ricavi pari a 64,32 Mln € e un utile netto di -10,16 Mln €
(EUR) settembre 2026
YoY
Ricavi 64,32 Mln 63,12%
Utile lordo 53,78 Mln 78,21%
Utile netto -10,16 Mln 76,56%
EBITDA -10,13 Mln 73,74%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
3,73 Mld €
Numero di azioni
87,89 Mln
Massimo/minimo a 52 settimane
55,20 € - 18,32 €
Dividendi No
Beta
2,02
Rapporto P/E
-50,70
Rapporto PEG
-0,81
Rapporto P/B
14,40
Rapporto P/S
17,18

Profilo aziendale

HeartFlow, Inc., una società di tecnologia medicale, fornisce soluzioni non invasive per la diagnosi e la gestione delle malattie delle arterie coronarie in tutto il mondo. La sua piattaforma HeartFlow utilizza l'intelligenza artificiale e la fluidodinamica computazionale per creare un modello 3D personalizzato del cuore del paziente a partire da un'unica angiografia coronarica con tomografia computerizzata, un tipo specializzato di scansione che fornisce immagini dettagliate delle arterie del cuore. La piattaforma dell'azienda fornisce informazioni sul flusso sanguigno, sulla stenosi e sul volume e la composizione della placca, superando i limiti dei tradizionali test di imaging non invasivi. L'azienda è stata fondata nel 2007 e ha sede a Mountain View, in California.

Nome
HeartFlow
CEO
John Farquhar
Sito web
Quotazione in borsa
07/08/2025
Dipendenti 843
🍪

Parqet  usa i cookie. Scopri di più